CING cingulate.com: Multiplikator Forward P/S

The forward P/S dynamics allow for a valuation of Cingulate Inc. (CING) based on synergies with research centers in the development of ADHD therapies. However, geopolitical logistics disruptions are hindering international trials, and a lack of internal cash flows leaves the company dependent on investments. Currently, this metric stands at , which helps objectively correlate market capitalization with expected revenue without reporting lags.

Cingulate Inc - Rasio kapitalisasi marang dodolan sing dikarepake CING (periode 04.07.2022 - 13.11.2026)

Rincian analitis lan laporan data perusahaan cingulate.com (CING)

- rega pasar lan target rega analis:

Bagan rega Cingulate|CING - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Cingulate Inc.|CING - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- statistik nilai buku emiten:

Nilai Buku saben Saham Cingulate|CING - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku cingulate.com|CING - Total Aset Bisnis

- data tingkat utang lan likuiditas finansial:

Total Utang marang Modal Cingulate Inc.|CING - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Cingulate|CING - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Cingulate Inc.|CING - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Cingulate|Indikator likuiditas cepet cingulate.com

- rincian asil keuangan lan kelipatan valuasi:

CING - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Cingulate Inc.|CING - Kapitalisasi marang bathi|Prakiraan rega marang bathi Cingulate|CING - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Cingulate Inc.|CING - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Cingulate|CING - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan cingulate.com|CING - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Cingulate Inc.

- indikator volume dodolan lan pendapatan:

CING - Pendapatan reged perusahaan|Prakiraan volume dodolan Cingulate|CING - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Cingulate Inc.

Analisis fundamental perusahaan:CING (Cingulate Corp)

The licensing prospects for the CTX-1301 drug for ADHD therapy make the forward revenue multiple a key indicator of market expectations regarding the future cash flows of Cingulate Inc. (CING). This chart compares current market capitalization with expected forward sales, allowing investors to perform a real-time assessment of the premium for potential clinical success and the pace of business scaling.

Karo sapa Cingulate Inc. saingan

Rasio rega marang prakiraan pendapatan Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|atai Life Sciences Corp - Multiplikator Forward P/S|GH Research Group (GHRS) - Multiplikator forward rega marang pendapatan|MNMD: Multiplikator Forward P/S|CMPS - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan LB Pharmaceuticals|Kapitalisasi marang prakiraan pendapatan DRUG (Bright Minds Bio)|Multiplikator Forward P/S VNDA|cybin.com (CYBN) - Prakiraan rega marang pendapatan|Alto Neuroscience, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S nrxpharma.com NRXP|SILO - Rasio rega marang prakiraan pendapatan|CPHI: Rasio rega marang prakiraan pendapatan|CMND: Multiplikator Forward P/S|Psyence Bio (PBM) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan SPRC|SEEL (seelostherapeutics.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S VRPX|KRTX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep